OXIS INTERNATIONAL, INC. is completing a strategic and timely transformation towards its goal of becoming a leading nutraceutiecal, cosmecuetical and therapeutics company.

OXIS was founded in 1966 and for many years focused on diagnostics while developing some of its unique patented compounds and acquiring significant expertise in the field of oxidative stress including ERGO.

OXIS is now focusing its business on its rich science background and its related 12 key patents and 7 patent pending applications and other new research.

During the past twelve months, OXIS has made significant strides towards its new objectives including:

• Divesting all of it diagnostics businesses to strategically focus the business on neutraceuticals, cosmeceuticals and therapeutic compounds,
• Building a new strong team of Executive Management, Board of Directors, and Scientific Advisory Board,
• Raising new capital to fund its new strategy, and
• Increasing the equity value and liquidity of its common stock and regaining Bulletin Board trading status.

Investors and others interested in learning more about OXIS are invited to review the following additional information.